Yeztugo (lenacapavir) HIV vaccine

2025: Product Announcement

On June 18, 2025, the American pharmaceutical company Gilead Sciences introduced the drug Yeztugo (lenacapavir) to protect against HIV. It is claimed that this agent provides 100 percent effectiveness.

Yeztugo is an injectable drug that requires administration twice a year. It prevents infection with the human immunodeficiency virus through sexual contact. The reliability of the tool is supported by the results of two large-scale studies in which people at high risk of HIV infection took part. One involved 2,179 people who received the vaccine subcutaneously twice a year. Among the participants in this group, only two cases of HIV infection were identified, which indicates a 99.9 percent level of protection. In the second group of 2,134 participants, no one contracted HIV, indicating 100 percent reliability.

𝓲

Фото: Freepik

This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthroughs of our time, it offers a real opportunity to help end the HIV epidemic, says Daniel O'Day, Chairman and CEO of Gilead Sciences.

It is also noted that Yeztugo shows 89% higher efficacy than Truvada (tenofovir/emtricitabine), which is also developed by Gilead Sciences and is available as tablets. The U.S. Food and Drug Administration (FDA) has approved the drug Yeztugo for use. The cost of the annual course will be $28,218, that is, each injection will cost $14,109.

We are working to make Yeztugo available to anyone who needs it or wants to use it and are counting on coverage, a Gilead spokesperson said.[1]

Notes